# Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer

> **NCT00853684** · PHASE2 · UNKNOWN · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 44 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** OXCE
- **DRUG:** Endostar

## Key facts

- **NCT ID:** NCT00853684
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-02
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2009-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853684, "Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00853684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*